ClinicalTrials.gg
RecruitingNCT05835505DOLPHINUpdated Jul 21, 2026

Detoxification of the Liver In PSC (Dolphin)

A Phase 2 interventional study of BRS201 and Placebo in Primary Sclerosing Cholangitis, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Cholangitis, Sclerosing with a site in United States — 20 open to participants now, 23 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.

Planned enrollment
27th of 58
28 · median 27
Started
2023
with 3 others
Phase 2
26 of 76
6 open now
Primary completion
2027-05
later than 5 of 22 live
Registered
63rd of 76
by date
Lead sponsor
5 of 76
Brigham and Women's Hospital

Among the 76 studies in Cholangitis, Sclerosing with a site in United States, this one is the 27th largest by planned enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2023, is one of 26 in phase 2, reaches primary completion later than 5 of the 22 other live ones, and was the 63rd registered.

Cholangitis, Sclerosing

152 studies on the registry are indexed under Cholangitis, Sclerosing; 42 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

20 of the 76 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Cholangitis, Sclerosing with a site in United States, or all of them as a file.
02

Study summary

This study is a clinical trial being done to investigate the efficacy of drug BRS201 (hydroxocobalamin) as a treatment in patients with primary sclerosing cholangitis. Participation in this study will take 8 weeks long and the study is structured as a cross-over study in which participants will take the study drug for 4 weeks and a placebo drug for 4 weeks in a randomized order in the form of an oral medication. Participation may also involve receiving an IV dose of the medication. The study will require participants to attend 9 study visits, all of which will be remote. Participation will involve taking an oral medication twice daily, tracking the medication in a log, and getting blood drawn and giving a stool sample for a few lab tests throughout the study. For the lab tests, a research nurse will visit the participant in-home for the convenience of the participant.

03

Conditions studied

  • Primary Sclerosing Cholangitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of PSC for at least 6 months based upon cholangiography (ERCP or MRCP) demonstrating intrahepatic and/or extrahepatic biliary strictures, beading or irregularity consistent with PSC.
  • ALP > 1.5 times the (ULN) at screening.
  • Subject must either be on a stable dose of ursodeoxycholic acid for > 6 months prior to screening or have been discontinued > 4 weeks prior to screening (enrollment of patients who are on UDCA will be limited to 60% of all enrolled patients).

Exclusion criteria

Exclusion Criteria:

  • Anticipated need for liver transplant within one year as determined by Mayo PSC risk score
  • Evidence of decompensated liver disease such as variceal bleeding, ascites, or hepatic encephalopathy.
  • Evidence of advanced liver disease including MELD score > 10, > 3.0, count \< 100,000; or > 1.4
  • Concomitant chronic liver disease including alcohol related liver disease, chronic or C infection, haemochromatosis, Wilson's disease, alpha1-antitrypsin deficiency, non-alcoholic steatohepatitis, hepatitis, or primary biliary cholangitis
  • Secondary causes of sclerosing cholangitis
  • Patients who have a confirmed or cancer within 5 years except non-melanoma skin cancers
  • Treatment with any agents, within two months or 5 half-lives of the investigational product, whichever is longer.
  • Active illicit drug or more than moderate alcohol consumption.
  • Evidence of bacterial cholangitis within 6 months of enrollment
  • In patients with Ulcerative Colitis, or, if Crohn's disease, a need for additional therapy at time of screening.
  • Chronic kidney injury ( \< 60)
  • Pregnancy or lactation
  • Uncontrolled hypertension with a systolic BP > 140 and a systolic BP > 90
  • Prohibited medications: current use of vitamin C and prednisone
  • Patients with a history or risk of cardiovascular conditions, including arrhythmia, long syndrome, congestive heart failure, stroke, or coronary artery disease
  • Patients with a history of kidney stones
  • Congenital or acquired immunodeficiencies
  • Other comorbidities including: diabetes mellitus, systemic lupus
  • An episode of acute cholangitis within 4 weeks of screening Check eligibility here: https://redcap.link/Checkmyeligibility
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (estimated)

Study arms

  • Active comparator
    BRS201 Arm

    In Group 1 of the study, subjects will take oral study drug at 1.2g twice daily, PO (2.4g daily) for 4 weeks. In Group 2 of the study, subjects will take oral study drug at 2g twice daily, PO (4g daily) for 4 weeks. In Group 3 of the study, subjects will take receive a one-time 5g IV dose of the study drug using the FDA-approved IV product followed by the oral study drug at 2g twice daily, PO (4g daily) for 4 weeks. In Group 4 of the study, subjects will repeat the previous conditions of the group that proves to be the most effective.

    Drug: BRS201

  • Placebo comparator
    Placebo Arm

    In Group 1 of the study, subjects will take oral placebo at 1.2g twice daily, PO (2.4g daily) for 4 weeks. In Group 2 of the study, subjects will take oral placebo at 2g twice daily, PO (4g daily) for 4 weeks. In Group 3 of the study, subjects will take receive a one-time 5g IV dose of the study drug using the FDA-approved IV product followed by the oral placebo at 2g twice daily, PO (4g daily) for 4 weeks. In Group 4 of the study, subjects will repeat the previous conditions of the group that proves to be the most effective.

    Drug: Placebo

Interventions

  • DrugBRS201

    Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.

  • DrugPlacebo

    Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.

06

What researchers measure

Primary outcomes

  1. Alkaline Phosphatase (ALP) Test Result

    The primary endpoint for this study is the capacity of BRS201 to normalize alkaline phosphatase levels from baseline (week 0) compared to end of active treatment (4 weeks).

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for May 2027, 40 months after the start.

Of 23 phase 2 interventional studies under Cholangitis, Sclerosing, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 62. This study's planned 40 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2023
First posted
Apr 28, 2023
StartActual
Dec 12, 2023
Primary completionEst.
May 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05835505
Responsible party
Joshua Korzenik (Director, Crohn's and Colitis Center, Brigham and Women's Hospital) — Principal investigator
First posted
Apr 28, 2023
Start date
Dec 12, 2023
Primary completion
May 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jul 21, 2026

Study contacts

Sophie Mitchell, BS
Contact
smitchell22@bwh.harvard.edu
5089363674
Siani Ellis, BS
Contact
pscresearch@bwh.harvard.edu
6177325500 ext. 29281
Joshua A Korzenik, MD
principal investigator · Brigham and Womens Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion